Infinity Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals

INFI 0.0160

-4.8%

Sep 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (27)	5/8/2006 2:39:57 PM
From: Mike McFarland	Read Replies (1) of 210

drugdisc.com Discovery and Development of IPI-504, A Potent Inhibitor of Hsp90 Case Study IPI-504 is an aqueous soluble (>200 mg/mL) hydroquinone hydrochloride salt of 17-allylamino-17-demethoxy-geldanamycin (17-AAG), an Hsp90 inhibitor that is the subject of multiple clinical trials for the treatment of cancer. The IPI-504 hydroquinone binds to Hsp90 more tightly than the 17-AAG quinone, however it undergoes a redox interconversion with 17-AAG in cells and in vivo that result in a dynamic equilibrium of the two chemical species. Various hydroquinone analogs have been prepared to investigate the structure activity relationship of hydroquinone binding to Hsp90. The favorable pharmacological properties of IPI-504 have led to the initiation of Phase I clinical trials. James R. Porter, Ph.D., Senior Scientist, Medicinal Chemistry, Infinity Pharmaceuticals, Inc. ........................ I found the pdf here: giichinese.com.tw Gene Logic is a sponsor--and also has good presence at the meeting. Iconix too. 454 caught my eye, I do not see Solexa. a big fwiw

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next